Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

News

31 - 40of about 655 News

June 08, 2021

Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson’s disease

June 03, 2021

Not intended for U.S. and UK Media

Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer

May 27, 2021

Bayer announces five-point plan to effectively address potential future Roundup™ claims

May 25, 2021

Not intended for U.S. and UK Media

Precision oncology treatment Larotrectinib submitted for marketing authorization in China

May 21, 2021

Not intended for U.S. and UK Media

Positive CHMP opinion for Bayer’s new symptomatic chronic heart failure treatment vericiguat

May 19, 2021

Not intended for U.S. and UK Media - ASCO Annual Meeting 2021:

Long-term data on Vitrakvi™ (larotrectinib) confirm sustained clinical benefit of greater than four years in patients with TRK fusion cancer regardless of tumor type and age

May 17, 2021

BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases

May 17, 2021

Not intended for U.S. and UK Media - Late-Breaking Data from exploratory analysis of Phase III FIDELIO-DKD study presented at the American College of Cardiology’s (ACC) 70th Annual Scientific Session (ACC.21)

Finerenone has potential to reduce the risk of new onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes